TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22806399

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice per day
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg once per day
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice per day (treatment-extension phase)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg once per day (treatment-extension phase)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Placebo re-randomized to apremilast (treatment-extension phase)
Number of subjects: 204
Study: 19708095

Group type: EXPERIMENTAL
Intervention: Randomized patients (241 out of 502 eligible)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Overall population of operated patients (1309)
Number of subjects: 502
Study: 17549325

Group type: EXPERIMENTAL
Intervention: Neck Disability Index
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Northwick Park Pain Questionnaire
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Copenhagen Neck Functional Disability Scale
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Neck Pain and Disability Scale
Number of subjects: 102
Study: 16447934

Group type: EXPERIMENTAL
Intervention: VISX Star S2 excimer laser (n = 22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Asclepion-Meditec MEL 70 G Scan excimer laser (n = 21)
Number of subjects: 43
Study: 15547304

Group type: EXPERIMENTAL
Intervention: Thrombolysis during cardiopulmonary resuscitation
Number of subjects: 0
Study: 11120434

Group type: EXPERIMENTAL
Intervention: Monetary reinforcement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Facial feedback
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of reinforcement and facial feedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repeated practice
Number of subjects: 40
Study: 8782347

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the abbreviated schedule (two vaccinations given 2 weeks apart)
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the standard schedule (two vaccinations given 4 weeks apart)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen) with other 'travellers' vaccines
Number of subjects: 2036
Study: 1509550

Group type: EXPERIMENTAL
Intervention: Propofol (Diprivan) with prior administration of 4 micrograms/kg fentanyl
Number of subjects: 96

Group type: COMPARATOR
Intervention: Propofol (Diprivan) without prior administration of fentanyl
Number of subjects: 96
Study: 6838691

Group type: EXPERIMENTAL
Intervention: Diet and/or drugs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treatment patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deterioration in tests
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 40
Study: 30690546

Group type: EXPERIMENTAL
Intervention: Manual chest percussion technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mechanical chest wall vibrator
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 46
Study: 27280502

Group type: EXPERIMENTAL
Intervention: Drain management protocol for pancreatoduodenectomy (PD) with selective drain placement and early drain removal based on risk stratification.
Number of subjects: 260
Study: 26198893

Group type: EXPERIMENTAL
Intervention: Illusory kinesthesia group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 24949549

Group type: EXPERIMENTAL
Intervention: SOD-melon concentrate (10 mg per day for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (starch only for 12 weeks)
Number of subjects: 61
Study: 23176987

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Tracheal intubation (TT)
Number of subjects: 204
Study: 19399705

Group type: EXPERIMENTAL
Intervention: High-dose (HD) nifedipine; 20 mg loading dose, repeated in 30 minutes, daily 120 to 160 mg slow-release nifedipine for 48 hours followed by 80 to 120 mg daily until 36 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Low-dose (LD) nifedipine; 10 mg, up to four doses every 15 minutes, daily 60 to 80 mg slow-release nifedipine for 48 hours followed by 60 mg daily until 36 weeks
Number of subjects: 102
Study: 17353978

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic fundoplication (RALF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional laparoscopic fundoplication (CLF)
Number of subjects: 40
Study: 14996412

Group type: EXPERIMENTAL
Intervention: Yun Zhi (50 mg/kg body weight) plus Danshen (20 mg/kg body weight) capsules
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study: 11430277

Group type: EXPERIMENTAL
Intervention: BSE instruction, personalized strategies to reduce barriers, monthly telephone reminders for 3 months
Number of subjects: 198
Study: 9481579

Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oestrogen only phase
Number of subjects: 0
Study: 8060466

Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 60
Study: 3382247

Group type: EXPERIMENTAL
Intervention: Ozone (0.5 ppm)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 41
Study: 31424395

Group type: EXPERIMENTAL
Intervention: PF-06751979 275 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06751979 50 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06751979 125 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06751979 540 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06751979 275 mg multiple doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06751979 100 mg QD
Number of subjects: 0
Study: 28510491

Group type: EXPERIMENTAL
Intervention: FP/FORM 100/10 μg b.i.d. with AeroChamber Plus® Flow‐Vu® Spacer
Number of subjects: 48

Group type: COMPARATOR
Intervention: FP pMDI (Flixotide®) 100 μg b.i.d. with Volumatic® spacer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Extra-fine BDP breath-actuated inhaler (Aerobec®/QVAR® Autohaler®) 100 μg b.i.d.
Number of subjects: 48
Study: 27163964

Group type: EXPERIMENTAL
Intervention: Purple-fleshed potato meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yellow-fleshed potato meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilberry meal
Number of subjects: 0
Study: 23972645

Group type: EXPERIMENTAL
Intervention: Uncoated mini‐tablets
Number of subjects: 306

Group type: COMPARATOR
Intervention: Syrup
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Coated mini‐tablet
Number of subjects: 306
Study: 21431422

Group type: EXPERIMENTAL
Intervention: Informed guilty participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informed innocent participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less explicit information
Number of subjects: 0
Study: 19141998

Group type: EXPERIMENTAL
Intervention: FX60 dialyser
Number of subjects: 33

Group type: COMPARATOR
Intervention: HF80 dialyser
Number of subjects: 33
Study: 17823672

Group type: EXPERIMENTAL
Intervention: Buprenorphine (1 mL injected into the joint space)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (1 mL injected into the joint space)
Number of subjects: 40
Study: 15559732

Group type: EXPERIMENTAL
Intervention: Choice of coping strategies for arm shock
Number of subjects: 0

Group type: COMPARATOR
Intervention: No choice of coping strategies for arm shock
Number of subjects: 0
Study: 12351466

Group type: EXPERIMENTAL
Intervention: Soy protein 30 g/day, isoflavones 132 mg/day
Number of subjects: 32
Study: 10399205

Group type: EXPERIMENTAL
Intervention: Robust and model-based versions of score test and Wald test for assessing proportional odds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wald test based on fitting separate multiple logistic regression models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Score test requiring fitting just the proportional odds model
Number of subjects: 0
Study: 8530758

Group type: EXPERIMENTAL
Intervention: Expected reassurance condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unexpected-no reassurance condition
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 36
Study: 2177041

Group type: EXPERIMENTAL
Intervention: Itraconazole (4 mg per 1 kg of body weight, once daily for 6 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 15
Study: 6996516

Group type: EXPERIMENTAL
Intervention: Alcohol (three doses) during follicular phase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alcohol (three doses) during luteal phase
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 10
Study: 31865042

Group type: EXPERIMENTAL
Intervention: PARP inhibitor (veliparib)
Number of subjects: 32
Study: 30560515

Group type: EXPERIMENTAL
Intervention: Youth COMPASS program (5-week web- and mobile-delivered intervention)
Number of subjects: 249
Study: 28500019

Group type: EXPERIMENTAL
Intervention: Electronic version of the EORTC QLQ-H&N35
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paper version of the EORTC QLQ-H&N35
Number of subjects: 10
Study: 26262586

Group type: EXPERIMENTAL
Intervention: Exercise training plus low dose of dopamine agonists (DA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Exercise training plus placebo
Number of subjects: 14
Study: 23621675

Group type: EXPERIMENTAL
Intervention: Extended-release diclofenac
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acetaminophen and ibuprofen
Number of subjects: 62
Study: 21712706

Group type: EXPERIMENTAL
Intervention: Fractionated dose (F) group: paclitaxel (100 mg/m(2)) and carboplatin (AUC=3) on days 1 and 8
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonfractionated (NF) dose group: paclitaxel (200 mg/m(2)) and carboplatin (AUC=6) on day 1
Number of subjects: 27

Group type: COMPARATOR
Intervention: NF group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: F group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 19523690

Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Generic Environmental Supports (GES)
Number of subjects: 120

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 120
Study: 17524721

Group type: EXPERIMENTAL
Intervention: Meal-based version of the quick list
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unstructured version of the quick list
Number of subjects: 18
Study: 15455406

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 100 microg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 11438328

Group type: EXPERIMENTAL
Intervention: 0.060 mg Org 30659
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.120 mg Org 30659
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.180 mg Org 30659
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.240 mg Org 30659
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.075 mg desogestrel (reference group)
Number of subjects: 81
Study: 9127118

Group type: EXPERIMENTAL
Intervention: Rizatriptan (MK-462)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-HT
Number of subjects: 0
Study: 8246266

Group type: EXPERIMENTAL
Intervention: Sera from CF patients with elevated serum IgG
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IgG1, IgG2, or IgG4-enriched fractions
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IgG3-enriched fractions from CF patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sera from CF patients with low serum IgG
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sera from healthy controls
Number of subjects: 21
Study: 3527712

Group type: EXPERIMENTAL
Intervention: Spinal block
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 115

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 115
Study: 31122537

Group type: EXPERIMENTAL
Intervention: Crystalloid coload at 37 °C (Group W)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crystalloid coload at room temperature (Group RT)
Number of subjects: 60
Study: 28472240

Group type: EXPERIMENTAL
Intervention: Goserelin (gonadotropin-releasing hormone agonist) administered before and during chemotherapy
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no goserelin)
Number of subjects: 202
Study: 26035199

Group type: EXPERIMENTAL
Intervention: 150 mg venlafaxine + 60‐minute light of 7000 lux daily at 7:00 AM (venlafaxine + bright light therapy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 150 mg venlafaxine daily at 7:00 AM
Number of subjects: 50
Study: 23965217

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study: 21251178

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 1 mg or higher doses
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 0.3 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 0.05, 0.3, 1, 3, 5, or 8 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY)
Number of subjects: 43
Study: 19254299

Group type: EXPERIMENTAL
Intervention: Contemporary techniques for denture fabrication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deliberate prescription of impression materials
Number of subjects: 0
Study: 17804441

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study: 15042453

Group type: EXPERIMENTAL
Intervention: Autologous iliac-crest bone grafts
Number of subjects: 79

Group type: COMPARATOR
Intervention: Allogenic fibular bone grafts
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Two-level fusions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: One-level fusions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 79
Study: 11119454

Group type: EXPERIMENTAL
Intervention: Heart failure patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 104
Study: 9314089

Group type: EXPERIMENTAL
Intervention: Tiazac (diltiazem HCl capsule formulation)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cardizem CD (extended-release diltiazem)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dilacor XR (extended-release diltiazem)
Number of subjects: 14
Study: 8353660

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg daily (5 mg morning and evening for 2 weeks)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 124
Study: 3319859

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CI)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (CSII and CI)
Number of subjects: 14
Study: 2195863

Group type: EXPERIMENTAL
Intervention: Dipyridamole 150 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 18
Study: 1149482

Group type: EXPERIMENTAL
Intervention: Eryfer (fast-release iron capsule) - 2 capsules (100 mg. elemental iron) daily for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ferro-Gradumet (slow-release iron tablet) - 1 tablet (105 mg. elemental iron) daily for 30 days
Number of subjects: 60
Study: 31874180

Group type: EXPERIMENTAL
Intervention: Late night sleep loss (four-hour sleep during the first night-half)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Early night sleep loss (four-hour sleep during the second night-half)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Regular sleep (eight-hour sleep)
Number of subjects: 11
Study: 31350934

Group type: EXPERIMENTAL
Intervention: FAB intervention (behavioral ED risk factor reduction program)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 481
Study: 28653586

Group type: EXPERIMENTAL
Intervention: High-protein meal replacement (HPMR)
Number of subjects: 122
Study: 26009990

Group type: EXPERIMENTAL
Intervention: Hands-free phone conversation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Handheld phone conversation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Baseline (no phone conversation)
Number of subjects: 100
Study: 24224449

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (vitamin C) supplementation at a dose of 600 mg per 24 hours during chemotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (24 healthy individuals)
Number of subjects: 25
Study: 21633770

Group type: EXPERIMENTAL
Intervention: Glutamine-added parenteral nutrition (PN)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Glutamine-added PN
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard PN
Number of subjects: 270
Study: 19541586

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 60
Study: 16979993

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (MPS) [1.08-1.44 g/d]
Number of subjects: 112

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) [1.5-2.0 g/d]
Number of subjects: 112
Study: 15520535

Group type: EXPERIMENTAL
Intervention: Automated monitoring system for chronic kidney-insufficient patients
Number of subjects: 0
Study: 10938494

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate CR/XL added to standard therapy
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 3991
Study: 9052464

Group type: EXPERIMENTAL
Intervention: Intravesical pentosanpolysulphate (PPS) 300 mg in 50 mL of 0.9% sodium chloride, applied twice a week for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravesical pentosanpolysulphate (PPS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (after stopping PPS)
Number of subjects: 20
Study: 8398961

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg in 25 ml dilution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (25 ml saline)
Number of subjects: 20
Study: 3742049

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/d for 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 16
Study: 30003481

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Gamification arm
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Gamification arm with PCP data sharing
Number of subjects: 196
Study: 28480658

Group type: COMPARATOR
Intervention: Hormonal Therapy (HT) alone (0.625 mg/day of conjugated equine estrogen and 2.5 mg/day of medroxyprogesterone acetate)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Combination treatment with Alendronate (ALEN) and Hormonal Therapy (HT) (10 mg/day of ALEN)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Combination treatment with Alendronate (ALEN) and Hormonal Therapy (HT)
Number of subjects: 344
Study: 25715019

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (PoCUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stethoscope
Number of subjects: 0
Study: 23991661

Group type: EXPERIMENTAL
Intervention: Dabigatran (initial doses of 150, 220, or 300 mg twice daily, adjusted based on kidney function)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Warfarin (doses adjusted to obtain an INR of 2 to 3 or 2.5 to 3.5)
Number of subjects: 252
Study: 20420722

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 53
Study: 19383314

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical characteristics
Number of subjects: 0
Study: 16621768

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation (4 g/m2/day) during chemotherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: No glutamine supplementation (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation
Number of subjects: 21
Study: 11957440

Group type: EXPERIMENTAL
Intervention: Intervention group (I group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 9795483

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 31
Study: 7861879

Group type: EXPERIMENTAL
Intervention: Routine feedback on test-group A (electrocardiography, endoscopy, cervical smears, and allergy tests)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Routine feedback on test-group B (radiographic and ultrasonographic tests)
Number of subjects: 79
Study: 2227076

Group type: EXPERIMENTAL
Intervention: 150 mg ursodeoxycholic acid (UDCA) twice daily for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 365214

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 15
Study: 30190512

Group type: EXPERIMENTAL
Intervention: Gene therapy (ADV-TK, 5 × 10^12/ml) administered one or two times before operation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Surgery alone (Control group)
Number of subjects: 77
Study: 29161072

Group type: EXPERIMENTAL
Intervention: HEART intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 222
Study: 26620101

Group type: EXPERIMENTAL
Intervention: BIT225 (400 mg twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21